Opthea (ASX:OPT) Presentation, FNN Investor Event, May 2018, Sydney

Company Presentations

Opthea Limited (ASX:OPT) Managing Director and CEO, Dr Megan Baldwin presents on the company's lead drug candidate OPT-302 for the treatment of wet age-related macular degeneration and diabetic macular edema.

Key points:

- Novel technology and therapy for eye disease
- OPT-302, a new approach for the treatment of wet AMD and DME
- Market opportunity >USD$10 billion worldwide
- Safety of OPT-302
- Evidence of improved vision and reductions in fluid
- Currently enrolling patients in two randomised, controlled clinical trials
- Phase 2b wet AMD and Phase 1b/2a DME studies
- Trials are recruiting patients in US, EU, Israel and Australia

For more, watch the Managing Director and CEO Dr Megan Baldwin, present.

Subscribe to our Daily Newsletter?

Would you like to receive our daily news to your inbox?